<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Abbott Laboratories — News on 6ix</title>
<link>https://6ix.com/company/abbott-laboratories</link>
<description>Latest news and press releases for Abbott Laboratories on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sat, 25 Apr 2026 16:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/abbott-laboratories" rel="self" type="application/rss+xml" />
<item>
<title>Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026</title>
<link>https://6ix.com/company/abbott-laboratories/news/abbott-showcases-strength-of-its-technologies-to-address-abnormal-heart-rhythms-with-late-breaking-clinical-data-at-heart-rhythm-society-2026</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/abbott-showcases-strength-of-its-technologies-to-address-abnormal-heart-rhythms-with-late-breaking-clinical-data-at-heart-rhythm-society-2026</guid>
<pubDate>Sat, 25 Apr 2026 16:30:00 GMT</pubDate>
<description>Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios to treat heart rhythm disorders.</description>
</item>
<item>
<title>Catheters Market Report 2025-2030, Profiles and Strategy Analysis of Leading Players - Abbott Laboratories, Boston Scientific, Medtronic, Terumo, and B. Braun</title>
<link>https://6ix.com/company/abbott-laboratories/news/catheters-market-report-2025-2030-profiles-and-strategy-analysis-of-leading-players-abbott-laboratories-boston-scientific-medtronic-terumo-and-b-braun</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/catheters-market-report-2025-2030-profiles-and-strategy-analysis-of-leading-players-abbott-laboratories-boston-scientific-medtronic-terumo-and-b-braun</guid>
<pubDate>Thu, 23 Apr 2026 10:08:00 GMT</pubDate>
<description>The catheter market is poised for significant growth due to rising chronic disease prevalence, increased minimally invasive procedures, and enhanced healthcare access in emerging regions. Opportunities lie in product innovation, particularly in advanced coatings and diagnostic features, and expansion strategies in Asia-Pacific and other developing areas. Catheters Market Catheters Market Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- The "Catheters Market" report has been added to ResearchAndMarkets</description>
</item>
<item>
<title>New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test</title>
<link>https://6ix.com/company/abbott-laboratories/news/new-data-at-aacr-2026-demonstrate-advancements-in-cancerguardr-multi-cancer-early-detection-test</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/new-data-at-aacr-2026-demonstrate-advancements-in-cancerguardr-multi-cancer-early-detection-test</guid>
<pubDate>Fri, 17 Apr 2026 19:30:00 GMT</pubDate>
<description>Abbott (NYSE: ABT) will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating continued advancements in its multi-biomarker, multi-cancer early detection (MCED) program supporting the commercially available Cancerguard® test. Additionally, the AACR Cancer Prevention Research Award for Outstanding Journal Article will recognize a publication on MCED multiyear outcomes from the DETECT-A study.</description>
</item>
<item>
<title>Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences</title>
<link>https://6ix.com/company/abbott-laboratories/news/abbott-reports-first-quarter-2026-results-updates-guidance-to-reflect-acquisition-of-exact-sciences</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/abbott-reports-first-quarter-2026-results-updates-guidance-to-reflect-acquisition-of-exact-sciences</guid>
<pubDate>Thu, 16 Apr 2026 11:30:00 GMT</pubDate>
<description>Abbott today (NYSE: ABT) announced financial results for the first quarter ended March 31, 2026.</description>
</item>
<item>
<title>New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health</title>
<link>https://6ix.com/company/abbott-laboratories/news/new-survey-finds-most-americans-believe-chronic-diseases-are-preventable-but-only-1-in-4-feel-confident-in-how-to-care-for-their-health</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/new-survey-finds-most-americans-believe-chronic-diseases-are-preventable-but-only-1-in-4-feel-confident-in-how-to-care-for-their-health</guid>
<pubDate>Thu, 09 Apr 2026 13:00:00 GMT</pubDate>
<description>Today, Abbott (NYSE: ABT), a global leader in chronic disease prevention, treatment and care, is releasing new survey findings highlighting a growing tension: 74% of U.S. adults believe most chronic diseases, such as diabetes or cardiovascular disease, are preventable, but only 1 in 4 feel very confident in knowing how to care for their health.</description>
</item>
<item>
<title>Global Medical Nutrition Market to Reach USD 31.1 Billion by 2035, Driven by Preventive Healthcare Across North America, Europe & Asia-Pacific - Key Players Nestlé, Abbott, Danone & DSM Lead Innovation</title>
<link>https://6ix.com/company/abbott-laboratories/news/global-medical-nutrition-market-to-reach-usd-311-billion-by-2035-driven-by-preventive-healthcare-across-north-america-europe-and-asia-pacific-key-players-nestle-abbott-danone-and-dsm-lead-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/global-medical-nutrition-market-to-reach-usd-311-billion-by-2035-driven-by-preventive-healthcare-across-north-america-europe-and-asia-pacific-key-players-nestle-abbott-danone-and-dsm-lead-innovation</guid>
<pubDate>Tue, 31 Mar 2026 14:16:00 GMT</pubDate>
<description>According to a latest market analysis by Future Market Insights, the global medical nutrition market is projected to grow from USD 17.2 billion in 2025 to USD 31.1 billion by 2035, registering a CAGR of 6.1%. Growth is being driven by rising chronic diseases, increasing adoption of preventive healthcare, and growing awareness of personalized nutrition.</description>
</item>
<item>
<title>Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform</title>
<link>https://6ix.com/company/abbott-laboratories/news/abbott-expands-access-to-precision-oncology-portfolio-through-integration-with-flatirons-oncoemrr-platform</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/abbott-expands-access-to-precision-oncology-portfolio-through-integration-with-flatirons-oncoemrr-platform</guid>
<pubDate>Mon, 30 Mar 2026 13:00:00 GMT</pubDate>
<description>Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott's comprehensive Precision Oncology portfolio into OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platform.</description>
</item>
<item>
<title>Abbott hosts conference call for first-quarter earnings</title>
<link>https://6ix.com/company/abbott-laboratories/news/abbott-hosts-conference-call-for-first-quarter-earnings</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/abbott-hosts-conference-call-for-first-quarter-earnings</guid>
<pubDate>Thu, 26 Mar 2026 13:00:00 GMT</pubDate>
<description>Abbott (NYSE: ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens.</description>
</item>
<item>
<title>John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening</title>
<link>https://6ix.com/company/abbott-laboratories/news/john-stamos-and-jodie-sweetin-reunite-for-the-second-talk-with-cologuardr-tests-encouraging-colon-cancer-screening</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/john-stamos-and-jodie-sweetin-reunite-for-the-second-talk-with-cologuardr-tests-encouraging-colon-cancer-screening</guid>
<pubDate>Tue, 24 Mar 2026 12:00:00 GMT</pubDate>
<description>Abbott (NYSE: ABT) today announced a new campaign encouraging people to stop avoiding awkward conversations about colorectal cancer. The company is reuniting beloved sitcom family members, John Stamos and Jodie Sweetin, for "The (Second) Talk" campaign – because when it comes to colon cancer screening, even adults need another trusted adult for advice.</description>
</item>
<item>
<title>Abbott completes acquisition of Exact Sciences</title>
<link>https://6ix.com/company/abbott-laboratories/news/abbott-completes-acquisition-of-exact-sciences</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/abbott-completes-acquisition-of-exact-sciences</guid>
<pubDate>Mon, 23 Mar 2026 12:50:00 GMT</pubDate>
<description>Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people.</description>
</item>
<item>
<title>Abbott acquisition of Exact Sciences set to close on March 23, 2026</title>
<link>https://6ix.com/company/abbott-laboratories/news/abbott-acquisition-of-exact-sciences-set-to-close-on-march-23-2026</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/abbott-acquisition-of-exact-sciences-set-to-close-on-march-23-2026</guid>
<pubDate>Fri, 20 Mar 2026 13:00:00 GMT</pubDate>
<description>Abbott (NYSE: ABT) today announced that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026. The announcement follows receipt of all regulatory clearances necessary for closing.</description>
</item>
<item>
<title>Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management</title>
<link>https://6ix.com/company/abbott-laboratories/news/landmark-study-shows-libre-technology-helps-people-with-type-2-diabetes-on-basal-insulin-improve-glucose-management</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/landmark-study-shows-libre-technology-helps-people-with-type-2-diabetes-on-basal-insulin-improve-glucose-management</guid>
<pubDate>Thu, 12 Mar 2026 12:00:00 GMT</pubDate>
<description>Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology had better glucose outcomes than those using traditional fingersticks. Improvements were achieved through participant-led self-management, guided by real-time CGM insights. Findings were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (AT</description>
</item>
<item>
<title>Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'</title>
<link>https://6ix.com/company/abbott-laboratories/news/abbott-and-real-madrid-launch-nationwide-effort-to-build-the-next-abbott-dream-team</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/abbott-and-real-madrid-launch-nationwide-effort-to-build-the-next-abbott-dream-team</guid>
<pubDate>Wed, 11 Mar 2026 15:00:00 GMT</pubDate>
<description>Abbott (NYSE: ABT) announced today the launch of the second year of the 'Abbott Dream Team,' encouraging young soccer players aged 18–19 across the United States to sign up for the chance to take part in a once-in-a-lifetime development experience in Madrid. Selected participants will train with Real Madrid's world‑renowned coaches at the club's facilities and enjoy unique opportunities, including attending a Real Madrid match at the Bernabéu Stadium and meeting club legends. Building on the suc</description>
</item>
<item>
<title>Point of Care Diagnostics Market Competitive Landscape Report 2025 Featuring Top 5 Players - Sysmex, Abbott Laboratories, Becton Dickinson and Co, Danaher, Quidel Diagnostics</title>
<link>https://6ix.com/company/abbott-laboratories/news/point-of-care-diagnostics-market-competitive-landscape-report-2025-featuring-top-5-players-sysmex-abbott-laboratories-becton-dickinson-and-co-danaher-quidel-diagnostics</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/point-of-care-diagnostics-market-competitive-landscape-report-2025-featuring-top-5-players-sysmex-abbott-laboratories-becton-dickinson-and-co-danaher-quidel-diagnostics</guid>
<pubDate>Tue, 24 Feb 2026 11:36:00 GMT</pubDate>
<description>By 2033, the Point of Care (POC) Diagnostics market is projected to reach a valuation of approximately US$ 105.22 billion, driven by an 8.60% CAGR from 2025. This robust growth is fueled by high demand for rapid and accessible testing, escalating global prevalence of infectious diseases, and breakthroughs in technology. POC diagnostics facilitate immediate results at patient care sites, enhancing clinical decision-making and patient outcomes. Key players leading this market, including Sysmex, Ab</description>
</item>
<item>
<title>Abbott declares 409th consecutive quarterly dividend</title>
<link>https://6ix.com/company/abbott-laboratories/news/abbott-declares-409th-consecutive-quarterly-dividend</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/abbott-declares-409th-consecutive-quarterly-dividend</guid>
<pubDate>Fri, 20 Feb 2026 16:38:00 GMT</pubDate>
<description>The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.</description>
</item>
<item>
<title>Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation</title>
<link>https://6ix.com/company/abbott-laboratories/news/late-breaking-data-presentations-showcase-the-safety-and-efficacy-of-abbotts-ablation-catheters-to-treat-people-with-atrial-fibrillation</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/late-breaking-data-presentations-showcase-the-safety-and-efficacy-of-abbotts-ablation-catheters-to-treat-people-with-atrial-fibrillation</guid>
<pubDate>Fri, 06 Feb 2026 13:00:00 GMT</pubDate>
<description>Abbott (NYSE: ABT) today announced new clinical data from two late-breaking presentations at AF Symposium in Boston (February 5-7, 2026) that demonstrate the strong safety and efficacy of the company's minimally invasive therapies to treat people with atrial fibrillation (AFib). The results include 12-month findings that reinforce the long-term safety and performance of Abbott's Volt™ Pulsed Field Ablation (PFA) System, which were simultaneously published in JACC: Clinical Electrophysiology. Pos</description>
</item>
<item>
<title>Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook</title>
<link>https://6ix.com/company/abbott-laboratories/news/abbott-reports-fourth-quarter-full-123000765</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/abbott-reports-fourth-quarter-full-123000765</guid>
<pubDate>Thu, 22 Jan 2026 12:30:00 GMT</pubDate>
<description>Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2025.</description>
</item>
<item>
<title>Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms</title>
<link>https://6ix.com/company/abbott-laboratories/news/abbott-receives-ce-mark-for-the-tactiflextm-duo-ablation-catheter-to-treat-patients-with-abnormal-heart-rhythms</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/abbott-receives-ce-mark-for-the-tactiflextm-duo-ablation-catheter-to-treat-patients-with-abnormal-heart-rhythms</guid>
<pubDate>Tue, 20 Jan 2026 14:00:00 GMT</pubDate>
<description>Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ to treat patients with atrial fibrillation (AFib). Following the new approval, the first successful commercial cases using TactiFlex Duo in the European Union were completed this week.</description>
</item>
<item>
<title>TorHoerman Law Announces $495 Million Jury Verdict in Case Involving Abbott Laboratories</title>
<link>https://6ix.com/company/abbott-laboratories/news/torhoerman-law-announces-495-million-121500538</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/torhoerman-law-announces-495-million-121500538</guid>
<pubDate>Fri, 16 Jan 2026 12:15:00 GMT</pubDate>
<description>A Missouri jury awarded damages following claims related to infant formula and necrotizing enterocolitis (NEC), according to court proceedings. ST. LOUIS, MO / ACCESS Newswire / January 16, 2026 / TorHoerman Law, a national injury litigation law firm, ...</description>
</item>
<item>
<title>Abbott's FreeStyle Libre 3 Plus Now Covered Across Canada</title>
<link>https://6ix.com/company/abbott-laboratories/news/abbotts-freestyle-libre-3-plus-now-covered-across-canada</link>
<guid isPermaLink="true">https://6ix.com/company/abbott-laboratories/news/abbotts-freestyle-libre-3-plus-now-covered-across-canada</guid>
<pubDate>Wed, 07 Jan 2026 14:00:00 GMT</pubDate>
<description>Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in every province across Canadavi, in federal plans like Non-Insured Health Benefits (NIHB)vi and by a majority of employer-sponsored workplace benefits programs.i Coverage means more Canadians living with diabetes can experience the ease of the world's smallest glucose sensor.iv,v</description>
</item>
</channel>
</rss>